Denna sida på svenska

Thomas Hatschek

Associated

Visiting address : Byggnad Z1:01, Karolinska Universititetssjukhuset Solna 171 76 Stockholm, Sweden

Publications

Contrast-enhanced ultrasound (CEUS) in assessing early response among patients with invasive breast cancer undergoing neoadjuvant chemotherapy
Saracco A, Szabó Bk, Tánczos E, Bergh J, Hatschek T
Acta radiologica (Stockholm, Sweden : 1987) 2017;58(4):394-402

Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
Rosell J, Nordenskjöld B, Bengtsson No, Fornander T, Hatschek T, Lindman H, et al
Acta oncologica (Stockholm, Sweden) 2017;56(4):614-617

Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer
Zetterlund Lh, Frisell J, Zouzos A, Axelsson R, Hatschek T, De Boniface J, et al
Breast cancer research and treatment 2017;163(1):103-110

Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer
Fotoohi Ak, Karim H, Lafolie P, Pohanka A, Östervall J, Hatschek T, et al
Therapeutic drug monitoring 2016;38(2):239-45

Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Kimbung S, Johansson I, Danielsson A, Veerla S, Egyhazi Brage S, Frostvik Stolt M, et al
Clinical cancer research : an official journal of the American Association for Cancer Research 2016;22(1):146-57

Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications
Kimbung S, Kovács A, Danielsson A, Bendahl Po, Lövgren K, Frostvik Stolt M, et al
Oncotarget 2015;6(32):33306-18

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
Tobin Np, Harrell Jc, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, et al
Annals of oncology : official journal of the European Society for Medical Oncology 2015;26(1):81-8

Audio-recorded information to patients considering participation in cancer clinical trials - a randomized study
Bergenmar M, Johansson H, Wilking N, Hatschek T, Brandberg Y
Acta oncologica (Stockholm, Sweden) 2014;53(9):1197-204

Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences
Kimbung S, Kovács A, Bendahl Po, Malmström P, Fernö M, Hatschek T, et al
Molecular oncology 2014;8(1):119-28

Validation of a novel procedure for quantification of the formation of phosphoramide mustard by individuals treated with cyclophosphamide
Von Stedingk H, Xie H, Hatschek T, Foukakis T, Rydén A, Bergh J, et al
Cancer chemotherapy and pharmacology 2014;74(3):549-58

When is the deep inferior epigastric artery flap indicated for breast reconstruction in patients not treated with radiotherapy?
Lundberg J, Thorarinsson A, Karlsson P, Ringberg A, Frisell J, Hatschek T, et al
Annals of plastic surgery 2014;73(1):105-13

Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel
Linderholm Bk, Lidbrink E, Tallroth E, Einbeigi Z, Svensson H, Von Wachenfeldt A, et al
Breast (Edinburgh, Scotland) 2013;22(6):1142-7

Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
Rosell J, Nordenskjöld B, Bengtsson No, Fornander T, Hatschek T, Lindman H, et al
Breast cancer research and treatment 2013;138(2):467-73

Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy
Suzuki C, Blomqvist L, Hatschek T, Carlsson L, Einbeigi Z, Linderholm B, et al
Medical oncology (Northwood, London, England) 2013;30(1):415-

No differences between Calendula cream and aqueous cream in the prevention of acute radiation skin reactions--results from a randomised blinded trial
Sharp L, Finnilä K, Johansson H, Abrahamsson M, Hatschek T, Bergenmar M
European journal of oncology nursing : the official journal of European Oncology Nursing Society 2013;17(4):429-35

Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
Bjöhle J, Bergqvist J, Gronowitz Js, Johansson H, Carlsson L, Einbeigi Z, et al
Breast cancer research and treatment 2013;139(3):751-8

Smoking as an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer
Sharp L, Johansson H, Hatschek T, Bergenmar M
Breast (Edinburgh, Scotland) 2013;22(5):634-8

Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
Lindstrom Ls, Karlsson E, Wilking Um, Johansson U, Hartman J, Lidbrink Ek, et al
JOURNAL OF CLINICAL ONCOLOGY 2012;30(21):2601-8

Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer
Svensson H, Hatschek T, Johansson H, Einbeigi Z, Brandberg Y
Medical oncology (Northwood, London, England) 2012;29(2):432-8

Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
Hatschek T, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Lindh B, et al
Breast cancer research and treatment 2012;131(3):939-47

When to order a biopsy to characterise a metastatic relapse in breast cancer
Foukakis T, Astrom G, Lindstrom L, Hatschek T, Bergh J
ANNALS OF ONCOLOGY 2012;:x349-53

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, et al
Breast cancer research and treatment 2011;125(2):553-61

Pattern of care in locally advanced breast cancer: Focus on local therapy
Sinacki M, Badzio A, Welnicka-jaskiewicz M, Bogaerts J, Piccart Mj, Therasse P, et al
BREAST 2011;20(2):145-50

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
Rosell J, Nordenskjöld B, Bengtsson No, Fornander T, Hatschek T, Lindman H, et al
British journal of cancer 2011;104(6):899-902

Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria
Suzuki C, Torkzad Mr, Jacobsson H, Aström G, Sundin A, Hatschek T, et al
Acta oncologica (Stockholm, Sweden) 2010;49(4):509-14

Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)
Svensson H, Einbeigi Z, Johansson H, Hatschek T, Brandberg Y
Breast cancer research and treatment 2010;123(3):785-93

Psychological reactions to progression of metastatic breast cancer--an interview study
Svensson H, Brandberg Y, Einbeigi Z, Hatschek T, Ahlberg K
Cancer nursing 2009;32(1):55-63

Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer: a national survey performed at pathology departments in Sweden
Rydén L, Haglund M, Bendahl Po, Hatschek T, Kolaric A, Kovács A, et al
Acta oncologica (Stockholm, Sweden) 2009;48(6):860-6

A phase II trial of docetaxel (Taxotere (R)) as second-line chemotherapy in patients with metastatic breast cancer
Baur M, Van Oosterom At, Dieras V, Tubiana-hulin M, Coombes Rc, Hatschek T, et al
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 2008;134(2):125-35

Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
Einbeigi Z, Bergström D, Hatschek T, Malmberg M
Clinical medicine. Oncology 2008;2():533-8

Radiologic measurements of tumor response to treatment: practical approaches and limitations
Suzuki C, Jacobsson H, Hatschek T, Torkzad Mr, Bodén K, Eriksson-alm Y, et al
Radiographics : a review publication of the Radiological Society of North America, Inc 2008;28(2):329-44

A five-year follow-up of quality of life in women with breast cancer in anthroposophic and conventional care
Carlsson M, Arman M, Backman M, Flatters U, Hatschek T, Hamrin E
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2006;3(4):523-31

Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial
Nordenskjöld B, Rosell J, Rutqvist Le, Malmström Po, Bergh J, Bengtsson No, et al
Journal of the National Cancer Institute 2005;97(21):1609-10

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Ebctcg, Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, et al
LANCET 2005;365(9472):1687-717

Evaluation of quality of life/life satisfaction in women with breast cancer in complementary and conventional care
Carlsson M, Arman M, Backman M, Flatters U, Hatschek T, Hamrin E
Acta oncologica (Stockholm, Sweden) 2004;43(1):27-34

Individuals with an increased risk of colorectal cancer: perceived benefits and psychological aspects of surveillance by means of regular colonoscopies
Liljegren A, Lindgren G, Brandberg Y, Rotstein S, Nilsson B, Hatschek T, et al
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(9):1736-42

Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels
Se Sweden Breast Canc Grp, Ferno M, Stal O, Baldetrop B, Hatschek T, Kallstrom Ac, et al
BREAST CANCER RESEARCH AND TREATMENT 2000;59(1):69-76

Efficacy of pamidronate in breast cancer with bone metastases: A randomized, double-blind placebo-controlled multicenter study
Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren Ub, et al
ANTICANCER RESEARCH 1999;19(4C):3383-92

Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications
Karlsson Ya, Malmström Po, Hatschek T, Fornander Tg, Söderberg M, Bengtsson No, et al
Cancer 1998;83(5):936-47

Frequent allelic losses on chromosome 13q in human male breast carcinomas
Wingren S, Van Den Heuvel A, Gentile M, Olsen K, Hatschek T, Soderkvist P
EUROPEAN JOURNAL OF CANCER 1997;33(14):2393-6

Histopathology grading in small breast cancers <=10mm - results from an area with mammography screening
Arnesson Lg, Hatschek T, Smeds S, Grontoft O
BREAST CANCER RESEARCH AND TREATMENT 1997;44(1):39-46

Improved survival with preoperative radiotherapy in resectable rectal cancer
Pahlman L, Glimelius B, Cedermark B, Lundell G, Rubio C, Rutqvist Le, et al
NEW ENGLAND JOURNAL OF MEDICINE 1997;336(14):980-7

A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor
Smith I, Jones A, Spielmann M, Namer M, Green Md, Bonneterre J, et al
BRITISH JOURNAL OF CANCER 1996;74(3):479-81

Local recurrence rate in a randomised multicentre trial of preoperative radiotherapy compared with operation alone in resectable rectal carcinoma
Pahlman L, Glimelius B, Cedermark B, Lundell G, Rieger A, Rutquist Le, et al
EUROPEAN JOURNAL OF SURGERY 1996;162(5):397-402

Nordic Ciba Cancer Care Workshop - Treatment of advanced breast cancer - Stockholm, January 18-19, 1996 - Foreword
Hatschek T, Blomqvist C, Lonning Pe, Rose C
ACTA ONCOLOGICA 1996;35(5):3-4

Ovarian ablation in early breast cancer: Overview of the randomised trials
Clarke M, Collins R, Davies C, Godwin J, Gray R, Peto R, et al
LANCET 1996;348(9036):1189-96

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
Rutqvist Le, Hatschek T, Ryden S, Bergh J, Bengtsson No, Carstenssen J, et al
JOURNAL OF THE NATIONAL CANCER INSTITUTE 1996;88(21):1543-9

Second-line endocrine treatment of advanced breast cancer--a randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide
Hultborn R, Johansson-terje I, Bergh J, Glas U, Hallsten L, Hatschek T, et al
Acta oncologica (Stockholm, Sweden) 1996;35 Suppl 5():75-

EFFECTS OF RADIOTHERAPY AND SURGERY IN EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS
Abe O, Abe R, Asaishi K, Enomoto K, Hattori T, Iino Y, et al
NEW ENGLAND JOURNAL OF MEDICINE 1995;333(22):1444-1455

P53 AS A PROGNOSTIC FACTOR IN STAGE-I BREAST-CANCER
Stenmarkaskmalm M, Stal O, Olsen K, Nordenskjold B, Arnesson Lg, Hatschek T, et al
BRITISH JOURNAL OF CANCER 1995;72(3):715-719

RE - DETERMINANTS OF PAPILLARY CANCER OF THE THYROID - REPLY
Wingren G, Axelson O, Hatschek T
AMERICAN JOURNAL OF EPIDEMIOLOGY 1995;141(9):883-884

Show all publications